Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab

Furer, Victoria; Zisman, Devy; Kaufman, Ilana; Arad, Uri; Berman, Mark; Sarbagil-Maman, Hagit; Elias, Muna; Hadad, A.; Paran, Daphna; Drori, Yaron; Friedman, Nehemya; Mandelboim, Michal; Elkayam, Ori

doi:10.1016/j.vaccine.2019.10.081

Cited by 32 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few, albeit limited, studies evaluating the effect of vaccination and its complications in patients using secukinumab [56][57][58]. The effect of inactive vaccines, including the humoral immune response, was not found to be different from the healthy population.…”

Section: Vaccines and Il-17 Inhibitorsmentioning

confidence: 99%

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has occupied the world agenda since December 2019. With no effective treatment yet, vaccination seems to be the most effective method of prevention. Recently developed vaccines have been approved for emergency use only and are currently applied to large populations. Considering both the underlying pathogenic mechanisms of autoimmune/ autoinflammatory rheumatological diseases (AIIRDs) and the immunosuppressive drugs used in treatment, vaccination for COVID-19 deserves special attention in such patients. In this article, we aimed to give simple messages to the clinicians for COVID-19 vaccination in patients with AIIRDs based upon the current evidence regarding the use of other vaccines in this patient group. For this purpose, we conducted a "Pubmed search" using the following keywords: Influenza, Hepatitis B, Pneumococcal, and Shingles vaccines and the frequently used conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Likewise, an additional search was performed for the COVID-19 immunization in patients with AIIRDs and considering such drugs. In summary, patients with AIIRDs should also be vaccinated against COVID-19, preferably when disease activity is under control and when there is no concurrent infection. Low-degree immunosuppression does not appear to decrease antibody responses to vaccines. Ideally, vaccinations should be done before the initiation of any biological DMARDs. Patients receiving rituximab should be vaccinated at least 4 weeks before or 6 months after treatment. Since tofacitinib may also reduce antibody responses, especially in combination with methotrexate, it may be appropriate to discontinue this drug before vaccination and to restart after 14 days of immunization.

show abstract

Section: Vaccines and Il-17 Inhibitorsmentioning

confidence: 99%

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is unlikely that these agents are disrupting the immune system's viral response in a way that would cause higher rates of COVID-19. Secukinumab does not disrupt patients' ability to develop a good response to seasonal influenza vaccines-evidence that the immune response to viruses can still operate correctly even with Il-17 inhibition (13,14). There is little difference in general infection rates between drug and placebo groups in IL-17 and IL-23 antagonist studies (15).…”

Section: Should Patients Stop Their Biologic Treatment During the Covmentioning

confidence: 99%

Should patients stop their biologic treatment during the COVID-19 pandemic

Bashyam

Feldman

2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

“…43,44 TNFi and tofacitinib do not significantly affect the humoral immune response to influenza vaccination but have been reported to result in both reduced and sufficient immune responses to the pneumococcal vaccine. [44][45][46][47][48] Abatacept, 49 ustekinumab, 50 and antieIL-17 treatment [51][52][53] do not interfere with the immune response to either influenza or pneumococcal vaccination, although large prospective studies of vaccine efficacy are lacking. No data were available at the time of analysis for cyclosporine (as used for psoriasis and other inflammatory diseases), antieIL-23 biologics, apremilast, or acitretin on the efficacy of any approved vaccine.…”

Section: Category 4: What Should Patients With Psoriatic Disease Do To Protect Themselves From Becoming Infected With Sars-cov-2?mentioning

confidence: 99%

A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases

Yan

Gaffney

Krain

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab

Cited by 32 publications

References 26 publications

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

Should patients stop their biologic treatment during the COVID-19 pandemic

A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases

Contact Info

Product

Resources

About